Ipsen, a leading French pharmaceutical company, has recently announced significant changes to its executive committee. Mari Scheiffele, a seasoned professional with a proven track record in commercial operations, is appointed as the new executive vice president and chief product officer. She will spearhead the development of innovative medicines in oncology and rare diseases, focusing on driving product development and pipeline innovation.
Scheiffele will also oversee globally renowned brands and life cycle management. This strategic move comes as Ipsen aims to strengthen its position in these critical therapeutic areas. Additionally, Andreas Gerber and Caroline Sitbon have been appointed as executive vice presidents, further enhancing Ipsen’s leadership team under the guidance of chief executive David Loew. These changes signal Ipsen’s commitment to driving forward-thinking strategies and fostering a culture of innovation within the organization.
Read more from thepharmaletter.com